Anal cancer screening - 13/01/15
Doi : 10.1016/j.jaad.2014.09.056
Alexander Kreuter, MD a, ⁎ 
, Stefan Esser, MD b, Ulrike Wieland, MD c
, Stefan Esser, MD b, Ulrike Wieland, MD c a Department of Dermatology, Venereology, and Allergology, HELIOS St Elisabeth Hospital Oberhausen, Oberhausen, Germany
b Department of Dermatology and Venerology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
c Institute of Virology, National Reference Center for Polyomaviruses and Papillomaviruses, University of Cologne, Germany
∗Correspondence to: Alexander Kreuter, MD, Department of Dermatology, Venereology, and Allergology, HELIOS St Elisabeth Hospital Oberhausen, Josefstrasse 3, 46045 Oberhausen, Germany
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosures: Dr Kreuter has served as a speaker for Meda Pharma, for which he received honoraria. He also serves on a scientific advisory board of MSD Sanofi Pasteur. Dr Esser takes part as local principal investigator in the Human Papillomavirus Quadrivalent Vaccine Study program of Merck and MSD Sanofi Pasteur. Dr Wieland has no conflicts of interest to declare. |
© 2014
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 72 - N° 2
P. 367-368 - février 2015 Retour au numéro
Article précédent
- Effect of recent Ebola outbreaks on estimating the global burden of diseases with skin manifestations
- Victoria Vaughan, Lindsay Boyers, Chante Karimkhani, Robert Dellavalle
- Response to: “Anal cancer screening”
- Walter Liszewski, Nicole Rogers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?